Results 151 to 160 of about 15,279 (220)

Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. [PDF]

Lancet Infect Dis
Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, Rosario N, Zhang Y, Mainou BA, Jimeno J, Aguirre G, Rüttimann R.   +11 more
europepmc   +1 more source

Immune predictors of oral poliovirus vaccine immunogenicity among infants in South India. [PDF]

NPJ Vaccines, 2020
Babji S, Manickavasagam P, Chen YH, Jeyavelu N, Jose NV, Praharaj I, Syed C, Kaliappan SP, John J, Giri S, Venugopal S, Kampmann B, Parker EPK, Iturriza-Gómara M, Kang G, Grassly NC, Uhlig HH.   +16 more
europepmc   +1 more source

Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.

Lancet Microbe
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin J, Arita M, Bandyopadhyay AS, Gast C, Sáez-Llorens X, Rüttimann RW, Van Damme P, De Coster I, Wright PF.   +14 more
europepmc   +1 more source

Expected RATE of Vaccine-Associated Paralytic Poliomyelitis: A Simulation Analysis Regarding Transition from the Trivalent to Bivalent Oral Poliovirus Vaccine.

Int J Prev Med, 2021
Yasri S, Wiwanitkit V.
europepmc   +1 more source

The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong Positive Selection and Tight Transmission Bottlenecks.

Cell Host Microbe, 2021
Valesano AL, Taniuchi M, Fitzsimmons WJ, Islam MO, Ahmed T, Zaman K, Haque R, Wong W, Famulare M, Lauring AS.   +9 more
europepmc   +1 more source

Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. [PDF]

NPJ Vaccines, 2020
Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, Smithee SE, Bujaki E, Te Yeh M, Laassri M, Zagorodnyaya T, Weiner AJ, Chumakov K, Andino R, Macadam A, Kew O, Burns CC.   +16 more
europepmc   +1 more source

The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus Vaccine [PDF]

, 2011

core   +1 more source

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial. [PDF]

Lancet
Ochoge M, Futa AC, Umesi A, Affleck L, Kotei L, Daffeh B, Saidy-Jah E, Njie A, Oyadiran O, Edem B, Jallow M, Jallow E, Donkor SA, Tritama E, Abid T, Jones KAV, Mainou BA, Konz JO, Fix A, Gast C, Clarke E.   +20 more
europepmc   +1 more source

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization. [PDF]

Clin Infect Dis, 2018
Sarnquist C, Holubar M, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Cruz-Hervert LP, Montero-Campos R, Altamirano J, Purington N, Boyle S, Modlin J, Ferreira-Guerrero E, Canizales-Quintero S, Díaz Ortega JL, Desai M, Maldonado YA.   +15 more
europepmc   +1 more source

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016.

Int J Infect Dis, 2021
Ahmad M, Verma H, Kunwar A, Soni S, Sinha U, Gawande M, Sethi R, Nalavade U, Sharma D, Bhatnagar P, Bahl S, Deshpande J.   +11 more
europepmc   +1 more source